Evidence map›Paper›PMID 35784749›Full record

ArticleFrontiers in pharmacology2022

Investigation of the Pharmacological Effect and Mechanism of Jinbei Oral Liquid in the Treatment of Idiopathic Pulmonary Fibrosis Using Network Pharmacology and Experimental Validation.

Aijun Zhang, Yixuan Zou, Qingcui Xu, Shuo Tian, Jie Wang, Yilin Li, Renchao Dong, Liangzong Zhang, Juanjuan Jiang, Lili Wang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Aijun ZhangInstitute of Chinese Materia Medica, Shandong Hongji-tang Pharmaceutical Group Co., Ltd., Jinan, China.
Yixuan ZouShandong University of Traditional Chinese Medicine, Jinan, China.
Qingcui XuInstitute of Chinese Materia Medica, Shandong Hongji-tang Pharmaceutical Group Co., Ltd., Jinan, China.
Shuo TianShandong University of Traditional Chinese Medicine, Jinan, China.
Jie WangShandong University of Traditional Chinese Medicine, Jinan, China.
Yilin LiShandong University of Traditional Chinese Medicine, Jinan, China.
Renchao DongShandong University of Traditional Chinese Medicine, Jinan, China.
Liangzong ZhangInstitute of Chinese Materia Medica, Shandong Hongji-tang Pharmaceutical Group Co., Ltd., Jinan, China.
Juanjuan JiangInstitute of Chinese Materia Medica, Shandong Hongji-tang Pharmaceutical Group Co., Ltd., Jinan, China.
Lili WangInstitute of Chinese Materia Medica, Shandong Hongji-tang Pharmaceutical Group Co., Ltd., Jinan, China.
Kai TaoInstitute of Chinese Materia Medica, Shandong Hongji-tang Pharmaceutical Group Co., Ltd., Jinan, China.
Zhaoqing MengInstitute of Chinese Materia Medica, Shandong Hongji-tang Pharmaceutical Group Co., Ltd., Jinan, China.
Yanqiu LiuShandong University of Traditional Chinese Medicine, Jinan, China.
Institute of Chinese Materia MedicaShandong University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

E-cadherinidiopathic pulmonary fibrosisjinbei oral liquidMAPKSnetwork pharmacologypulmonary functionvimentin

Identifiers

PMID35784749
PMCPMC9240387
OpenAlexW4282932709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.